trial
as of 2026-07-01Real-life Assessment of Abilify Maintena + Rexult in Schizophrenia
NCTId NCT05169268
at a glance
Phase — · Completed
Enrollment 6 (actual)
Sponsored by The University of Hong Kong
Primary completion 2026-01-31
Synthesized from structured facts only — each point cited above.
Design & status
Phase
—
Status
Completed
Enrollment
6 (actual)
Study type
Observational
Allocation
—
Model
—
Masking
—
Start
2022-02-01
Primary completion
2026-01-31
Eligibility
ALL · 18 Years · 65 Years
Interventions & indications
Sponsors
The University of Hong KongLead Sponsor
Investigators
1
albert KK Chung, DrPrincipal Investigator
Sites
1 total
Hong Kong, Hong Kong
Facts & assertions
4 sourced
Enrollment
6
Phase
NA
Primary Completion Date
2026-01-31
Status
COMPLETED
relationships
The graph out of here
drug
lead_sponsor
company
indication
investigator
person